GLP-1 Atlas is an independent, evidence-led clinical reference dedicated to GLP-1 receptor agonists and related incretin therapies. We translate landmark trial data, regulatory guidance and mechanistic science into a structured, freely accessible resource for healthcare professionals.
Our mission
GLP-1 medicines are among the most rapidly evolving therapies in medicine. Guidance, safety signals and the evidence base change quickly. Our mission is to keep clinicians oriented — accurately, without commercial bias, and in plain clinical language.
What we cover
- Mechanisms of action and incretin physiology
- Drug classes, pharmacokinetics and the development pipeline
- Landmark clinical trials across diabetes, obesity, cardiovascular and renal outcomes
- Prescribing guidelines, patient selection and shared decision-making
- Safety, adverse effects and special clinical scenarios
- Regulatory safety alerts from the MHRA, EMA, FDA and NICE
Editorial independence
GLP-1 Atlas is not funded, sponsored or directed by any pharmaceutical company. Content is produced and reviewed by Dr Kazmi, FRCP, author and clinical reviewer. Attribution is supplied by the site owner; no institutional endorsement is implied. See our editorial policy for how we source, review and update material.
How the site is funded
To keep this resource free, some pages may display advertising. Advertising is clearly labelled and never influences clinical content. Read how we handle data in our privacy policy and cookie policy.
Contact
Questions, corrections or feedback are welcome via our contact page.